Skip to main content
. 2023 Nov-Dec;39(6):1847–1852. doi: 10.12669/pjms.39.6.7944

Table-V.

Comparison of survival between groups (n, %).

Variables TACE+lenvatinib group (n=46) TACE group (n=57) χ2 P
OS
1-year survival 40 (86.96) 41 (71.93) 3.422 0.090
2-year survival 34 (73.91) 29 (50.88) 5.687 0.025
PFS
1-year PFS 35 (76.09) 35 (61.40) 2.521 0.139
2-year PFS 23 (50.00) 18 (31.58) 3.605 0.070